Pharma Veterans

AI and Machine Learning in Pharmaceutical Drug Development – Asrar Qureshi’s Blog Post #1102 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1102 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Credit: cottonbro studio Credit: Rui Dias Credit: YI REN This blogpost is inspired by interview of GSK’s Global Head of AI and Machine Learning, Kim Branson, by McKinsey panel. Link at the end Preamble The pharmaceutical industry is undergoing a profound transformation. With rising R&D costs, extended development timelines, and increasing regulatory scrutiny, innovation is no longer optional—it is essential. Among the most disruptive enablers of this transformation are Artificial Intelligence (AI) and Machine Learning (ML). These technologies are rapidly changing the way drugs are discovered, developed, and delivered. From e...

New Drug Modalities – Asrar Qureshi’s Blog Post 1047 Dear Colleagues! This is Asrar Qureshi’s Blog Post 1047 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com for publishing our contributions here. Credit: Edward Jenner Credit: Ivan Samkov Credit: Jonathan Borba This post is based on Boston Consulting Group article authored by Lu Chen, Brian Bush, Mike Brochu, and Gian King. Link at the end. Preamble The second annual report from BCG reviews the growth of new drug modalities. The report tracks the progress in each of the six categories of novel modalities in terms of number of products and pipeline revenue. It will help to see which modalities are progressing more rapidly and its implication for patients and biopharma companies and investors. For us in Pakistan, most of this may sound completely foreign, but we are already using many of these products. New Modalities L...

New Drugs Approvals – Asrar Qureshi’s Blog Post #929 Dear Colleagues! This is Asrar Qureshi’s Blog Post #929 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to aq.pharmaveterans@gmail.com for publishing your contributions here. Credit: Mikhail Nilov Credit: Pavel Danilyuk Credit: Polina Tankilevitch Periodically, I gather information and write a blog post about approval of new drugs in the USA, because it leads in the research, discovery, and commercialization of new, research products. Even if a pharmaceutical product is first registered in Europe, it is inevitably applied to USFDA for approval. USA also leads because it is the single largest market in the global pharma market. US accounts for about 47% of the world pharmaceutical market which is currently estimated to be about US$ 1.2 trillion. You can have an idea of the size.  The list of new drugs/ newer uses of existing drugs is given bel...

Growing Impact of Generative AI on Healthcare – Asrar Qureshi’s Blog Post #902 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #902 for Pharma Veterans. Pharma Veterans  aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Credit: This is Engineering Credit: Michelangelo Buonarotti Credit: Google Deepmind It is true that we are seriously behind in development and the gap between our country and the developed world is widening with passing time. However, in the digital space, we have generally been able to stay close to major developments. The irony is that the ills of technology reach us immediately, while the benefits take much longer and may or may not arrive fully. An important factor is that we prefer to use technology which comes free of cost, because we hate to pay f...

 Drug Development Update – Asrar Qureshi’s Blog Post #837 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #837 for Pharma Veterans. Pharma Veterans aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Photo Credit: Pavel Danilyuk Photo Credit: Pixabay Photo Credit: RF._. studio Periodically, I bring to you the update on new registrations by the USFDA. USFDA approval is most relevant because most research is happening in the US, and USFDA is mostly the first regulatory authority to approve new drugs, line extensions, new combinations, and expansion of indications. Some drugs are first applied to EMA – European Medicines Agency, but these are relatively few.  A look at new approvals is not just academic; it shows where the research is going, and where most investment is...

New Gene Therapy Products – Part 2 – Asrar Qureshi’s Blog Post #747 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #747 for Pharma Veterans. Pharma Veterans welcome sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Photo Credit: Gilmer Diaz Estela Photo Credit: Thirdman Photo Credit: Tiger Lily Gene therapy is among the newest modalities of treatment. It is still an experimental treatment that works by introducing genetic material into a person’s cell to fight or prevent disease. Gene Therapy is presently being tested for several diseases, such as autoimmune disorders, hemophilia, thalassemia, Parkinson’s disease, cancer, diabetes, heart disease, and so on. Gene therapy drugs are to be given as a single dose, only once in life.  We continue to look at some more drugs. CARVY...

Pfizer Success – Use of Technology – Asrar Qureshi’s Blog Post #673 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #673 for Pharma Veterans. Pharma Veterans welcome sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Lidia Fonseca COVID19 is fresh in our memories, so is the vaccines story. We received initially Chinese vaccines, Sinopharm and Sinovac which were not accepted even by UAE and Saudia. It worked well with us as we got it free from the government centers. Russian vaccine also became available at cost, and it also worked well. Chinese and Russian vaccines were based on standard technology.  Worldwide, Pfizer pioneered in developing the mRNA-based vaccine while Janssen and Astra Zeneca followed. The case of Pfizer-BioNTech vaccine is a case worth studying as it invol...